^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Lonsurf (trifluridine/tipiracil) (Thymidine phosphorylase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
107P - Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in previously treated metastatic colorectal cancer (mCRC): Results from the Australian cohort of the phase IIIb, international, open-label, early-access PRECONNECT study
Published date:
11/20/2020
Excerpt:
60% had RAS-mutant cancers...FTD/TPI was associated with a median PFS of 2.7 months (95% CI, 2.4–3.4) and disease control rate of 40% (95% CI, 28.47–52.41)….Results from the Australian cohort are consistent with the global PRECONNECT population and randomised datasets in previously treated mCRC patients.
Trial ID:
Source:
Title:
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Excerpt:
...receive TAS-102 or placebo and were stratified according to tumor status with regard to wildtype or mutant KRAS...The median overall survival improved from 5.3 months with placebo to 7.1 months with TAS-102, and the hazard ratio for death in the TAS-102 group versus the placebo group was 0.68 (95% confidence interval [CI], 0.58 to 0.81; P<0.001)...In patients with refractory colorectal cancer, TAS-102, as compared with placebo, was associated with a significant improvement in overall survival.
Trial ID:
Source:
Title:
Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer
Excerpt:
...Toxicity associated with TAS-102 combined with SBRT`Progression Free Survival`Overall Survival`Association between KRAS or BRAF mutation status with local control`Serial ctDNA...
Trial ID:
Source:
Title:
Study of Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Cancer in Asia
Excerpt:
...Progression-free Survival (PFS)`Time to Treatment Failure (TTF)`Overall Response Rate (ORR; Complete Response [CR] or Partial Response [PR] Using RECIST Criteria)`Disease Control Rate (DCR; CR, PR, or Stable Disease)`Duration of Response`Safety and Tolerability Evaluation Will Focus on Adverse Events and Laboratory Assessments（Adverse Events）`Safety and Tolerability Evaluation Will Focus on Adverse Events and Laboratory Assessments（Laboratory Assessments）`Overall Survival（OS）(Wild Type KRAS)`Overall Survival（OS）(Mutant Type KRAS)`Progression-free Survival (PFS) (Wild Type KRAS)`Progression-free Survival (PFS) (Mutant Type KRAS)...
Trial ID:
More C2 evidence
Source:
Title:
A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib and Panitumumab Versus Investigator's Choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Previously Treated Metastatic Colorectal Cancer Subjects with KRAS p.G12C Mutation Μια Πολυκεντρική, Τυχαιοποιημένη, Ανοιχτού Σχεδιασμού, Ελεγχόμενη με Δραστικό Φάρμακο Δοκιμή Φάσης 3 του Συνδυασμού Σοτορασίμπης και Πανιτουμουμάμπης Έναντι της Θεραπείας Επιλογής του Ερευνητή (Τριφλουριδίνη και Τιπιρακίλη, ή Ρεγοραφενίμπη) για την Αντιμετώπιση Ασθενών που Φέρουν τη Μετάλλαξη KRAS p.G12C και Είχαν Λάβει Προηγούμενη Θεραπεία για Μεταστατικό Ορθοκολικό Καρκίνο
Excerpt:
...101Subject has provided informed consent/assent prior to initiation of any study specific activities/procedures.102Age ≥ 18 years103Pathologically documented metastatic colorectal adenocarcinoma with KRAS p.G12C mutation as determined by central testing104Subjects will have received at least 1 prior line of therapy for metastatic disease. ...
Trial ID:
